Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00269594 · ClinicalTrials.gov registry record · Phase 2

An Open-Label Study Of Lamictal In Neurotic Excoriation

A Phase 2 study of Obsessive - Compulsive Disorder and Neurotic Disorders, sponsored by University of Minnesota.

Completed
Registry status
Phase 2
Development phase
25
Enrollment target
1
Study location

NCT00269594: Completed Phase 2 study of Obsessive - Compulsive Disorder and Neurotic Disorders, sponsored by University of Minnesota.

NCT00269594 is a Phase 2 study of Obsessive - Compulsive Disorder and Neurotic Disorders that has completed, run by University of Minnesota. The registered enrollment target is 25 participants, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00269594, a Phase 2 study of Obsessive - Compulsive Disorder and Neurotic Disorders, has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
Phase 2
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

The goal of the proposed study is to evaluate the efficacy and safety of Lamictal in neurotic excoriation. Twenty subjects with neurotic excoriation will receive 12 weeks of open-label treatment with Lamictal. The hypothesis to be tested is that Lamictal will be effective and well tolerated in patients with neurotic excoriation. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

Interventions

  • DRUG Lamictal (lamotrigine)

Study Locations (1)

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2006-01
Est. Completion 2006-09
Phase Phase 2
University of Minnesota

966 total trials

What the finished NCT00269594 record still lists

NCT00269594 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Lamictal (lamotrigine) is the first listed.

NCT00269594 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT00269594 about?

NCT00269594 is a clinical study titled "An Open-Label Study Of Lamictal In Neurotic Excoriation". The goal of the proposed study is to evaluate the efficacy and safety of Lamictal in neurotic excoriation. Twenty subjects with neurotic excoriation will receive 12 weeks of open-label treatment with Lamictal. The hypothesis to be tested is that Lamictal will be effective and well tolerated in patie...

What is the current status of trial NCT00269594?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2006-01. Estimated completion is 2006-09.

What conditions does trial NCT00269594 study?

This clinical trial studies the following conditions: Obsessive - Compulsive Disorder, Neurotic Disorders.

What interventions are being tested in trial NCT00269594?

The interventions under investigation include: Lamictal (lamotrigine) (DRUG).

Who is sponsoring clinical trial NCT00269594?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00269594 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obsessive - Compulsive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00269594's enrollment target sits among peer trials

25 69th of 84 higher than 16 of 84 other Obsessive - Compulsive Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obsessive - Compulsive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00269594, the US trial registry maintained by the National Library of Medicine. NCT00269594 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.